Actively Recruiting
Safety and Efficacy of Imatinib in Combination With Artemether-Lumefantrine for Uncomplicated Malaria
Led by Victoria Biomedical Research Institute · Updated on 2026-04-30
1116
Participants Needed
1
Research Sites
75 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is investigating an innovative approach to treating uncomplicated malaria by adding a drug called Imatinib to the current standard of care, Artemether + Lumefantrine (AL). The researchers hope this combination, known as ALIM, will clear infections faster and stop the spread of drug-resistant parasites that are becoming a major threat in Africa
CONDITIONS
Official Title
Safety and Efficacy of Imatinib in Combination With Artemether-Lumefantrine for Uncomplicated Malaria
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with symptomatic mild to moderate Plasmodium falciparum malaria with parasite density >= 5000 parasites/µl
- Adults aged 18 to 55 years who are male, or females aged 18 to 55 years who are post-menopausal or test negative on pregnancy and will use birth control during the study
- Provide informed consent and agree to hospital admission for 48 to 72 hours
- In good health aside from malaria
- Have not taken anti-malarial drugs in the past 4 weeks (adults)
- Children aged 12 months to less than 18 years with symptomatic mild to moderate malaria and parasite density >= 5000 parasites/µl
- Parent or legal representative consents to child's participation and hospital admission for 48 to 72 hours
- Child's hemoglobin levels greater than 5 mg/dL
- Child has not taken anti-malarial drugs in the past 6 weeks
You will not qualify if you...
- Decline to provide informed consent
- Symptoms or signs of severe or complicated malaria such as confusion, coma, multiple convulsions, respiratory distress, circulatory collapse, clinical jaundice with organ dysfunction, or other infections
- Parasite density greater than 200,000 parasites/µl
- Currently pregnant or breastfeeding (for females)
- Other neurological or psychiatric disorders
- Abnormal bleeding
- Resting heart rate below 55 or above 100 bpm
- History of heart disease
- Signs or lab results showing liver, lung, kidney, or cardiovascular impairment
- Abnormal blood chemistry including low hemoglobin, abnormal white or red blood cell counts, low platelets, or abnormal liver enzymes
- Symptoms of infections like pneumonia, dengue fever, or gastrointestinal infections affecting drug absorption
- Infection with Plasmodium species other than P. falciparum
- Unable to attend follow-up visits
- Use of certain medicines such as those for high cholesterol, hypertension, HIV, microbial infections, sleep aid, seizures, autoimmune diseases, depression, or nausea
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Victoria Biomedical Research Institute
Kisumu, Kenya, 40100
Actively Recruiting
Research Team
D
Dr. Quentin Awori, MBChB
CONTACT
D
David Ogolla Awori, Msc
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
5
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here